Are there differences in acute phase inflammation markers regarding the type of heart failure?
This study aimed to determine if there are differences in inflammatory markers in the acute phase between systolic heart failure and heart failure with preserved systolic function. One hundred and thirty-one patients with acute heart failure were recruited consecutively. At admission, plasma fibrinogen, Creactive protein, sialic acid, von Willebrand factor, vascular endothelial growth factor, interleukin-6 and NTproBNP were all evaluated. If the ejection fraction was 45% or over patients were included in the HF-PSF group; the remaining patients were included in the SHF group. The HF-PSF patients were older (72±10 vs 63±12 years, P<0.001), presented a higher rate of atrial fibrillation (56.1 vs 21.3%, P<0.001), and had a lower rate of hemoglobin (12.2±2 vs 13.3±2.1 g/dL, P<0.01). No significant differences were observed in the inflammation markers analyzed among SHF and HFPSF groups. In the acute phase of heart failure there is a marked elevation of inflammatory markers but there are no differences in the inflammatory markers analyzed between the two different types of heart failure.
Heart failure, inflammation
Ignacio J. Sánchez-Lázaro, Avda. Ausias March 2, esc. 2, pta. 15, 46111, Rocafort, Valencia, Spain. Tel. +34.629821756 – Fax: +34.961973314. E-mail: email@example.com
Share this Article
Related Content In Heart Failure
Measurement of Blood Volume in Patients with Heart Failure: Clinical Relevance, Surrogates, Historical Background and Contemporary Methodology
Heart International. 2023;17(1):Online ahead of journal publication
Heart failure (HF) is a common clinical diagnosis often requiring hospitalization secondary to patient decompensation associated with clinically determined ‘dry’ or ‘wet’ volume states. However, fluid overload is the more common basis for clinical deterioration accounting for the majority of hospitalizations.1–4 There is often a cycle of decompensation, compensation following intervention and then a recurrence of volume overload […]
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Comparison of Speckle Tracking Echocardiography During Different Pacing Modalities for Cardiac Resynchronization Therapy Response Prediction
Heart International. 2022;16(1):64–70 DOI: https://doi.org/10.17925/HI.2022.16.1.64
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (RV) pacing (RVP) system upgrade.1 The recommendations for CRT typically follow failure to improve after 3 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!